Company Encyclopedia
View More
name
NT PHARMA
01011.HK
China NT Pharma Group Company Limited, an investment holding company, engages in the investment, research and development, manufacture, sale, and distribution of pharmaceutical products in the People’s Republic of China. It operates through Digital Services and Sales Agency Service segments. The company acts as agent for clients to sell medical and health-related products to external customers. It also provides marketing and promotion in relation to bone health knowledge.
1.450 T
01011.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking41/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE22.76%A
    • Profit Margin-380.13%E
    • Gross Margin83.47%A
  • Growth ScoreD
    • Revenue YoY-40.29%E
    • Net Profit YoY48.27%B
    • Total Assets YoY3.56%C
    • Net Assets YoY18.59%A
  • Cash ScoreE
    • Cash Flow Margin-26.31%D
    • OCF YoY-40.29%E
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreE
    • Gearing Ratio180.39%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    China NT Pharma Appoints Li Yifang as Company Secretary and Authorised Representative

    China NT Pharma Group Co. Ltd. has appointed Ms. Li Yifang as the company secretary and authorised representative, effective November 25, 2025. This appointment was announced via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    01011
    +1.22%
    Reuters·
    HK
    01011
    +1.22%

    China NT Pharma Group Embraces AI for Orthopedic Market Transformation

    China NT Pharma Group Co., Ltd. is transforming into a high-tech medical enterprise using AI to capitalize on China's orthopedic market. The company aims to create a comprehensive healthcare ecosystem focusing on bone health, leveraging AI and national initiatives. Their offerings include AI-powered bone density analysis, orthopedic drugs, and digital healthcare services. The latest analyst rating for their stock (HK:1011) is a Hold with a HK$0.50 price target. The company has a market cap of HK$525.9M and a technical sentiment signal of Buy.

    Tip Ranks·
    HK
    01011
    +1.22%
    Tip Ranks·
    HK
    01011
    +1.22%

    China NT Pharma Group Announces Corporate Reorganization and Business Restructuring

    China NT Pharma Group Co. Ltd. has announced a corporate reorganization and business restructuring, focusing on innovative digital health services and bone health education. The company has disposed of its pharmaceutical manufacturing business to attract a wider customer base and deliver reliable returns. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

    Reuters·
    HK
    01011
    +1.22%
    Reuters·
    HK
    01011
    +1.22%

    NT PHARMA: Zheng Zhangjin resigns as company secretary, authorized representative, and legal process agent

    According to the Zhitong Finance APP, NT PHARMA announced that Mr. Zheng Zhangjin has resigned as the company's company secretary, authorized representative, and legal process agent, effective from October 17, 2025

    Zhitong·
    HK
    01011
    +1.22%
    Zhitong·
    HK
    01011
    +1.22%

    China NT Pharma Group Announces Resignation of Company Secretary and Key Representatives

    China NT Pharma Group Co. Ltd. announced the resignation of Mr. Cheng Cheung King as company secretary and key representative, effective October 17, 2025. The company is currently searching for a suitable replacement and will make an announcement upon appointment.

    Reuters·
    HK
    01011
    +1.22%
    Reuters·
    HK
    01011
    +1.22%
    © 2025 Longbridge｜Disclaimer